Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations.
暂无分享,去创建一个
M. Trucco | T. Medsger | C. Oddis | M. Trucco | W. Rudert | Y. Okano | R. Duquesnoy | W. Rudert
[1] T. Medsger,et al. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. , 1992, Arthritis and rheumatism.
[2] M. Dalakas,et al. A New Approach to the Classification of Idiopathic Inflammatory Myopathy: Myositis‐Specific Autoantibodies Define Useful Homogeneous Patient Groups , 1991, Medicine.
[3] J. Bodmer,et al. Nomenclature for factors of the HLA system, 1990. , 1991, Immunobiology.
[4] J. Reveille,et al. HLA-D region genes associated with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) and other translation-related factors in myositis. , 2010, Arthritis and rheumatism.
[5] T. Medsger,et al. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. , 1990, Arthritis and rheumatism.
[6] I. Targoff,et al. Antibody to signal recognition particle in polymyositis. , 1990, Arthritis and rheumatism.
[7] J. Rodríguez-Sánchez,et al. Identification of protein components reactive with anti‐PM/Scl autoantibodies , 1990, Clinical and experimental immunology.
[8] M. Meurer,et al. Immunogenetic associations of scleroderma-related antinuclear antibodies. , 1990, Arthritis and rheumatism.
[9] M. Dalakas,et al. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. , 1989, Annals of internal medicine.
[10] J. Todd,et al. Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[11] I. Targoff,et al. The association between Mi-2 antibodies and dermatomyositis. , 1985, Arthritis and rheumatism.
[12] J. F. Wolfe,et al. Clinical relevance of PM-1 antibody and physiochemical characterization of PM-1 antigen. , 1984, The Journal of rheumatology.
[13] F. Arnett,et al. Multiplicity of antibodies in myositis sera. , 1984, Arthritis and rheumatism.
[14] F. Arnett,et al. The Jo-1 antibody system in myositis: relationships to clinical features and HLA. , 1981, The Journal of rheumatology.
[15] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[16] James F. Fries,et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.
[17] H. Holman,et al. Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.
[18] J. Klippel,et al. A cutaneous lesion associated with myositis. , 1979, Annals of internal medicine.
[19] P. Terasaki,et al. Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. , 1978, American journal of clinical pathology.
[20] H. Paulus,et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. , 1978, Arthritis and rheumatism.
[21] J. F. Wolfe,et al. Antinuclear antibody with distinct specificity for polymyositis. , 1977, The Journal of clinical investigation.
[22] A. Bohan,et al. Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.
[23] A. Bohan,et al. Polymyositis and dermatomyositis (second of two parts). , 1975 .